Edition:
United Kingdom

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

35.11USD
18 Apr 2019
Change (% chg)

$0.20 (+0.57%)
Prev Close
$34.91
Open
$34.98
Day's High
$35.52
Day's Low
$34.36
Volume
2,363,833
Avg. Vol
1,903,971
52-wk High
$41.00
52-wk Low
$27.92

Latest Key Developments (Source: Significant Developments)

Boston Scientific Expects About $25 Mln Hit To 2019 Revenue From FDA Decision On Surgical Mesh Products
Wednesday, 17 Apr 2019 

April 17 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CORP - ANTICIPATES AN APPROXIMATE $25 MILLION NEGATIVE IMPACT GLOBALLY TO 2019 FULL YEAR REVENUE FROM FDA DECISION.BOSTON SCIENTIFIC CORP - CONTINUES TO ASSESS ANY POTENTIAL ADDITIONAL IMPACT TO BUSINESS FROM FDA DECISION ON SURGICAL MESH PRODUCTS.  Full Article

Boston Scientific Reports Q4 GAAP Earnings Per Share of $0.27
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2018.Q4 GAAP EARNINGS PER SHARE $0.27.Q4 SALES $2.561 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.56 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.37 -- REFINITIV IBES DATA.Q4 ADJUSTED EARNINGS PER SHARE $0.39.ESTIMATES REVENUE GROWTH FOR Q1 OF 2019, VERSUS PRIOR YEAR PERIOD, TO BE IN A RANGE OF APPROXIMATELY 6 TO 7 PERCENT.SEES Q1 EARNINGS ON A GAAP BASIS IN A RANGE OF $0.32 TO $0.33 PER SHARE.SEES Q1 ADJUSTED EARNINGS IN A RANGE OF $0.35 TO $0.36 PER SHARE.BOSTON SCIENTIFIC - ESTIMATES REVENUE GROWTH FOR 2019, VERSUS PRIOR YEAR PERIOD, TO BE IN A RANGE OF APPROXIMATELY 7 TO 9 PERCENT ON A REPORTED BASIS.ESTIMATES REVENUE GROWTH FOR 2019 OF APPROXIMATELY 7 TO 8.5 PERCENT ON AN ORGANIC BASIS.COMPANY ESTIMATES INCOME ON A GAAP BASIS IN A RANGE OF $1.13 TO $1.18 PER SHARE FOR 2019.ESTIMATES ADJUSTED EARNINGS IN A RANGE OF $1.53 TO $1.58 PER SHARE IN 2019.Q1 EARNINGS PER SHARE VIEW $0.37 -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.58 -- REFINITIV IBES DATA.  Full Article

Neovasc Announces Dismissal Of Claim Brought By Edwards Lifesciences
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Neovasc Inc ::NEOVASC ANNOUNCES DISMISSAL OF CLAIM BROUGHT BY EDWARDS LIFESCIENCES.  Full Article

Boston Scientific CEO Says Expects To Deliver Double Digit EPS Growth In 2018
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Boston Scientific Corp ::CEO SAYS EXPECT TO DELIVER DOUBLE DIGIT EPS GROWTH IN 2018 - JP MORGAN CONF.CEO SAYS NO CHANGES TO LAUNCH OF LOTUS SYSTEM; ON TRACK FOR Q1 LAUNCH IN EUROPE AND MID-YEAR IN U.S..CEO SAYS BTG PLC'S <<>> INTERVENTIONAL MEDICINE BUSINESS BRINGS MOST VALUE TO BSX.CEO EXPECTS TAX RATE OF 13 PERCENT AND FOREIGN EXCHANGE IMPACT TO BE NEUTRAL IN 2019 - JP MORGAN CONF.CEO SAYS WILL EXCEED ABOUT $1.1 BILLION IN RESEARCH AND DEVELOPMENT, WITH 30 PERCENT OF SPENDING IN CLINICAL PROJECTS - JP MORGAN CONF.  Full Article

Boston Scientific Preliminary Unaudited Q4 Sales $2.56 Bln Vs Refinitiv Estimate $2.56 Bln
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR 2018.Q4 SALES $2.56 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.56 BILLION.BOSTON SCIENTIFIC - FOR FULL YEAR 2018, GENERATED SALES, BASED UPON PRELIMINARY UNAUDITED FINANCIAL INFORMATION, OF ABOUT $9.82 BILLION.QTRLY SALES ROSE APPROXIMATELY 7.0 PERCENT ON AN ORGANIC BASIS.  Full Article

Boston Scientific Says Entered $2.75 Bln Revolving Credit Agreement
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CORP - ENTERED INTO A $2.750 BILLION REVOLVING CREDIT AGREEMENT - SEC FILING.BOSTON SCIENTIFIC CORP - REVOLVING CREDIT AGREEMENT MATURES ON DECEMBER 19, 2023.  Full Article

Appaloosa LP Dissolves Share Stake In NXP Semiconductors NV
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Appaloosa LP::APPALOOSA LP CUTS SHARE STAKE IN ALTABA INC BY 47.3 PERCENT TO 3.4 MILLION SHARES.APPALOOSA LP DISSOLVES SHARE STAKE IN WESTERN DIGITAL CORP.APPALOOSA LP DISSOLVES SHARE STAKE IN NXP SEMICONDUCTORS NV.APPALOOSA LP TAKES SHARE STAKE OF 1.2 MILLION SHARES IN STATE STREET CORP - SEC FILING.APPALOOSA LP DISSOLVES SHARE STAKE IN ALLY FINANCIAL INC.APPALOOSA LP CUTS SHARE STAKE IN BOSTON SCIENTIFIC CORP BY 66.2 PERCENT TO 853,875 SHARES.APPALOOSA LP - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Jana Partners Cuts Sole Share Stake In Boston Scientific, Autodesk
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Jana Partners LLC::JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN BOSTON SCIENTIFIC CORP BY 37.1 PERCENT TO ABOUT 2 MILLION SHARES.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN AUTODESK INC BY 58.9 PERCENT TO 366,830 SHARES.JANA PARTNERS LLC - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Edwards Lifesciences Corp Comments On German Court Decision
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Edwards Lifesciences Corp ::EDWARDS COMMENTS ON GERMAN COURT DECISION.EDWARDS LIFESCIENCES- DISTRICT COURT IN GERMANY, GRANTED BOSTON SCIENTIFIC'S REQUEST FOR A PRELIMINARY INJUNCTION ON FUTURE COMMERCIAL SALES.EDWARDS LIFESCIENCES CORP - INJUNCTION WILL ONLY BECOME EFFECTIVE IF BOSTON SCIENTIFIC ENFORCES IT AND PROVIDES A BOND OF EUR 10 MILLION.EDWARDS LIFESCIENCES-SAPIEN 3 ULTRA VALVE NOT YET APPROVED FOR COMMERCIAL SALE & SUBJECT OF CLINICAL STUDY FOR EUROPEAN APPROVAL, WHICH WILL CONTINUE.EDWARDS LIFESCIENCES CORP - COOURT'S DECISION HAS NO EFFECT ON SALES OF CO'S SAPIEN 3 OR CENTERA VALVES.  Full Article

Boston Scientific Prevails In German Edwards Lifesciences Litigation
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PREVAILS IN GERMAN EDWARDS LIFESCIENCES LITIGATION.BOSTON SCIENTIFIC - COURT RULES EDWARDS LIFESCIENCES' NEXT-GENERATION VALVE INFRINGES CO'S PATENT, GRANTS RIGHT TO ENJOIN SALES IN GERMANY.BOSTON SCIENTIFIC CORP - ANTICIPATES LOTUS EDGE VALVE SYSTEM WILL BE COMMERCIALIZED IN CE MARK COUNTRIES IN Q1 2019.BOSTON SCIENTIFIC - DISTRICT COURT OF DUSSELDORF DETERMINED THAT EDWARDS LIFESCIENCES CORPORATION'S SAPIEN 3 ULTRA DEVICE INFRINGED A PATENT.BOSTON SCIENTIFIC CORP - ANTICIPATES LOTUS EDGE VALVE SYSTEM WILL GET FDA APPROVAL TO BE SECURED IN MID-2019.  Full Article

Boston Scientific sees $25 million hit to 2019 revenue from mesh withdrawal

Boston Scientific Corp on Wednesday said it expects a setback of about $25 million to its full-year revenue due to the U.S. Food and Drugs Administration's order to halt sales of its transvaginal surgical mesh products.